Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Antirheumatic Agents | 25 | 2023 | 1339 | 4.680 |
Why?
|
Arthritis, Rheumatoid | 29 | 2023 | 3712 | 3.720 |
Why?
|
Drugs, Generic | 6 | 2020 | 421 | 2.870 |
Why?
|
Drug Prescriptions | 15 | 2021 | 1637 | 2.280 |
Why?
|
Medicare | 28 | 2023 | 6566 | 2.100 |
Why?
|
Angiotensin Receptor Antagonists | 6 | 2023 | 924 | 2.080 |
Why?
|
Heart Failure | 14 | 2023 | 10900 | 1.910 |
Why?
|
Cohort Studies | 67 | 2023 | 40561 | 1.640 |
Why?
|
Analgesics, Opioid | 16 | 2022 | 3674 | 1.590 |
Why?
|
Gout | 7 | 2023 | 573 | 1.460 |
Why?
|
Insurance Claim Review | 7 | 2021 | 720 | 1.450 |
Why?
|
Drug Utilization | 5 | 2020 | 1183 | 1.340 |
Why?
|
Pregnancy Complications | 18 | 2022 | 2861 | 1.340 |
Why?
|
Propensity Score | 17 | 2021 | 1781 | 1.320 |
Why?
|
Biological Products | 9 | 2022 | 860 | 1.290 |
Why?
|
United States | 81 | 2023 | 69872 | 1.240 |
Why?
|
Stroke Volume | 7 | 2023 | 5007 | 1.230 |
Why?
|
Renal Dialysis | 4 | 2021 | 1786 | 1.210 |
Why?
|
Medicaid | 16 | 2022 | 2736 | 1.180 |
Why?
|
Arthritis, Psoriatic | 6 | 2022 | 215 | 1.170 |
Why?
|
Allopurinol | 4 | 2021 | 191 | 1.160 |
Why?
|
Tumor Necrosis Factor-alpha | 8 | 2022 | 4420 | 1.140 |
Why?
|
Databases, Factual | 18 | 2022 | 7729 | 1.110 |
Why?
|
Medication Errors | 4 | 2013 | 798 | 1.100 |
Why?
|
Venous Thromboembolism | 5 | 2021 | 1671 | 1.030 |
Why?
|
Nursing Homes | 4 | 2013 | 1036 | 1.020 |
Why?
|
Piperidines | 4 | 2022 | 1602 | 0.980 |
Why?
|
Abnormalities, Drug-Induced | 8 | 2021 | 317 | 0.950 |
Why?
|
Immunologic Factors | 4 | 2022 | 1580 | 0.920 |
Why?
|
Renal Insufficiency, Chronic | 4 | 2023 | 2208 | 0.890 |
Why?
|
Cardiovascular Diseases | 16 | 2023 | 15165 | 0.890 |
Why?
|
Gout Suppressants | 3 | 2021 | 166 | 0.870 |
Why?
|
Famotidine | 1 | 2022 | 16 | 0.870 |
Why?
|
Anemia, Sickle Cell | 2 | 2020 | 1018 | 0.840 |
Why?
|
Insurance, Health | 4 | 2019 | 2494 | 0.840 |
Why?
|
Neprilysin | 2 | 2022 | 439 | 0.820 |
Why?
|
Research Design | 6 | 2023 | 5987 | 0.810 |
Why?
|
Pregnancy Trimester, First | 10 | 2021 | 853 | 0.780 |
Why?
|
Gastrointestinal Agents | 4 | 2022 | 494 | 0.780 |
Why?
|
Neonatal Abstinence Syndrome | 3 | 2022 | 109 | 0.780 |
Why?
|
Patient Preference | 2 | 2019 | 890 | 0.770 |
Why?
|
Biphenyl Compounds | 4 | 2023 | 913 | 0.770 |
Why?
|
Electronic Health Records | 11 | 2023 | 4468 | 0.750 |
Why?
|
Pyrimidines | 4 | 2022 | 2942 | 0.750 |
Why?
|
Drug Recalls | 1 | 2020 | 17 | 0.720 |
Why?
|
Heart Failure, Systolic | 1 | 2021 | 126 | 0.710 |
Why?
|
Hyperkalemia | 1 | 2022 | 218 | 0.710 |
Why?
|
Tetrazoles | 4 | 2023 | 835 | 0.710 |
Why?
|
Aged | 59 | 2023 | 163280 | 0.700 |
Why?
|
Humans | 147 | 2024 | 744343 | 0.700 |
Why?
|
Drug Utilization Review | 2 | 2018 | 245 | 0.700 |
Why?
|
Insurance, Pharmaceutical Services | 2 | 2020 | 336 | 0.700 |
Why?
|
Anticoagulants | 8 | 2023 | 4599 | 0.690 |
Why?
|
Drug Substitution | 2 | 2021 | 281 | 0.680 |
Why?
|
Hyperphosphatemia | 1 | 2019 | 40 | 0.680 |
Why?
|
Polypharmacy | 1 | 2021 | 294 | 0.670 |
Why?
|
Colitis, Ulcerative | 5 | 2022 | 1912 | 0.670 |
Why?
|
Osteoarthritis, Knee | 2 | 2019 | 1222 | 0.650 |
Why?
|
Drug Labeling | 1 | 2021 | 233 | 0.650 |
Why?
|
Immunosuppressive Agents | 6 | 2024 | 4149 | 0.640 |
Why?
|
Opioid-Related Disorders | 9 | 2022 | 2065 | 0.640 |
Why?
|
Calcium Phosphates | 1 | 2019 | 171 | 0.640 |
Why?
|
Adverse Drug Reaction Reporting Systems | 3 | 2023 | 469 | 0.620 |
Why?
|
Patient Acceptance of Health Care | 3 | 2020 | 3022 | 0.620 |
Why?
|
Spondylitis, Ankylosing | 2 | 2016 | 156 | 0.620 |
Why?
|
Chelating Agents | 1 | 2019 | 380 | 0.610 |
Why?
|
Alendronate | 2 | 2021 | 171 | 0.610 |
Why?
|
Female | 93 | 2023 | 380194 | 0.610 |
Why?
|
Atrial Fibrillation | 7 | 2023 | 5034 | 0.600 |
Why?
|
Prospective Payment System | 1 | 2018 | 133 | 0.600 |
Why?
|
Kidney Failure, Chronic | 2 | 2021 | 2538 | 0.600 |
Why?
|
Bone Density Conservation Agents | 3 | 2021 | 773 | 0.590 |
Why?
|
Osteoporotic Fractures | 2 | 2021 | 401 | 0.590 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 5 | 2020 | 3255 | 0.570 |
Why?
|
Rheumatic Diseases | 2 | 2020 | 592 | 0.560 |
Why?
|
Pyrroles | 2 | 2022 | 1146 | 0.560 |
Why?
|
Comparative Effectiveness Research | 3 | 2018 | 681 | 0.550 |
Why?
|
Marketing | 1 | 2018 | 212 | 0.540 |
Why?
|
Hydroxychloroquine | 8 | 2022 | 412 | 0.540 |
Why?
|
Psoriasis | 5 | 2022 | 898 | 0.540 |
Why?
|
Medicare Part D | 1 | 2020 | 328 | 0.530 |
Why?
|
Diabetic Nephropathies | 1 | 2023 | 984 | 0.530 |
Why?
|
Drug Approval | 2 | 2018 | 742 | 0.520 |
Why?
|
Male | 68 | 2023 | 350118 | 0.520 |
Why?
|
Platelet Aggregation Inhibitors | 2 | 2018 | 3068 | 0.520 |
Why?
|
Warfarin | 3 | 2023 | 1496 | 0.510 |
Why?
|
Congenital Abnormalities | 2 | 2017 | 707 | 0.510 |
Why?
|
Epidemiologic Research Design | 1 | 2018 | 367 | 0.510 |
Why?
|
Private Sector | 1 | 2018 | 392 | 0.500 |
Why?
|
Data Mining | 2 | 2023 | 537 | 0.500 |
Why?
|
Osteoarthritis, Hip | 1 | 2019 | 412 | 0.500 |
Why?
|
Treatment Outcome | 23 | 2023 | 63114 | 0.490 |
Why?
|
Acute Coronary Syndrome | 2 | 2018 | 2337 | 0.490 |
Why?
|
Crohn Disease | 3 | 2022 | 2303 | 0.490 |
Why?
|
Product Surveillance, Postmarketing | 1 | 2018 | 430 | 0.490 |
Why?
|
Purinergic P2Y Receptor Antagonists | 1 | 2017 | 361 | 0.490 |
Why?
|
Rheumatology | 2 | 2018 | 576 | 0.490 |
Why?
|
Epidemiologic Methods | 2 | 2017 | 1364 | 0.480 |
Why?
|
Arthroplasty, Replacement, Knee | 3 | 2022 | 1458 | 0.480 |
Why?
|
Computer Simulation | 6 | 2019 | 6196 | 0.470 |
Why?
|
Immune System Diseases | 1 | 2016 | 262 | 0.470 |
Why?
|
Diphosphonates | 1 | 2018 | 623 | 0.460 |
Why?
|
Prenatal Exposure Delayed Effects | 5 | 2022 | 2408 | 0.450 |
Why?
|
Uric Acid | 2 | 2023 | 766 | 0.450 |
Why?
|
Drug Combinations | 3 | 2023 | 1959 | 0.450 |
Why?
|
Medication Adherence | 3 | 2020 | 2063 | 0.450 |
Why?
|
Hip Fractures | 2 | 2018 | 955 | 0.440 |
Why?
|
Methadone | 1 | 2015 | 306 | 0.440 |
Why?
|
Guidelines as Topic | 1 | 2019 | 1405 | 0.430 |
Why?
|
Bone Marrow Transplantation | 1 | 2020 | 2765 | 0.430 |
Why?
|
Osteoporosis | 2 | 2021 | 1580 | 0.420 |
Why?
|
Proportional Hazards Models | 9 | 2021 | 12354 | 0.420 |
Why?
|
Diabetes Mellitus, Type 2 | 5 | 2023 | 11725 | 0.410 |
Why?
|
Inflammatory Bowel Diseases | 4 | 2022 | 2425 | 0.410 |
Why?
|
North Carolina | 4 | 2013 | 315 | 0.410 |
Why?
|
Pregnancy | 29 | 2022 | 29144 | 0.410 |
Why?
|
Risk Assessment | 15 | 2023 | 23338 | 0.410 |
Why?
|
Incidence | 14 | 2021 | 20947 | 0.410 |
Why?
|
Osteoarthritis | 1 | 2019 | 1036 | 0.400 |
Why?
|
Anticonvulsants | 6 | 2019 | 1916 | 0.390 |
Why?
|
Middle Aged | 45 | 2022 | 213383 | 0.390 |
Why?
|
Aged, 80 and over | 18 | 2022 | 57776 | 0.390 |
Why?
|
Diabetes Mellitus | 3 | 2018 | 5751 | 0.390 |
Why?
|
Azathioprine | 3 | 2024 | 353 | 0.380 |
Why?
|
Morphine | 1 | 2015 | 657 | 0.380 |
Why?
|
Ventricular Dysfunction, Left | 1 | 2021 | 2073 | 0.360 |
Why?
|
Drug Therapy, Combination | 5 | 2023 | 6489 | 0.360 |
Why?
|
Adult | 53 | 2024 | 214055 | 0.360 |
Why?
|
Pulmonary Embolism | 2 | 2021 | 2376 | 0.360 |
Why?
|
Hyperlipidemias | 1 | 2015 | 789 | 0.360 |
Why?
|
Social Class | 1 | 2019 | 1999 | 0.350 |
Why?
|
Acute Kidney Injury | 1 | 2022 | 1972 | 0.350 |
Why?
|
Probenecid | 2 | 2021 | 76 | 0.350 |
Why?
|
Logistic Models | 8 | 2020 | 13408 | 0.350 |
Why?
|
Venous Thrombosis | 1 | 2019 | 1239 | 0.350 |
Why?
|
Valine | 1 | 2011 | 413 | 0.350 |
Why?
|
Hospital Mortality | 2 | 2020 | 5317 | 0.340 |
Why?
|
Losartan | 1 | 2011 | 299 | 0.340 |
Why?
|
Glucocorticoids | 2 | 2022 | 2107 | 0.340 |
Why?
|
Stroke | 7 | 2023 | 9981 | 0.340 |
Why?
|
Analgesics | 2 | 2013 | 1040 | 0.340 |
Why?
|
Sulfasalazine | 2 | 2021 | 79 | 0.330 |
Why?
|
Methotrexate | 6 | 2022 | 1727 | 0.330 |
Why?
|
Risk Factors | 24 | 2023 | 72290 | 0.320 |
Why?
|
Hospitalization | 10 | 2023 | 10262 | 0.320 |
Why?
|
Administration, Oral | 3 | 2021 | 3913 | 0.310 |
Why?
|
Joint Diseases | 1 | 2011 | 480 | 0.300 |
Why?
|
Follow-Up Studies | 10 | 2020 | 39050 | 0.300 |
Why?
|
Adrenal Cortex Hormones | 1 | 2016 | 1855 | 0.290 |
Why?
|
Lithium Compounds | 2 | 2019 | 225 | 0.280 |
Why?
|
Health Care Costs | 1 | 2020 | 3209 | 0.280 |
Why?
|
Osteoporosis, Postmenopausal | 2 | 2021 | 386 | 0.280 |
Why?
|
Steroids | 1 | 2011 | 930 | 0.280 |
Why?
|
Antipsychotic Agents | 5 | 2018 | 3057 | 0.280 |
Why?
|
Benzimidazoles | 1 | 2011 | 850 | 0.270 |
Why?
|
Ventricular Function, Left | 1 | 2018 | 3670 | 0.270 |
Why?
|
Pain | 3 | 2017 | 4986 | 0.270 |
Why?
|
Severity of Illness Index | 4 | 2019 | 15540 | 0.270 |
Why?
|
Delivery of Health Care | 1 | 2024 | 5319 | 0.270 |
Why?
|
Vitamin D | 2 | 2022 | 3223 | 0.260 |
Why?
|
Registries | 4 | 2018 | 8089 | 0.260 |
Why?
|
Risk | 11 | 2021 | 9687 | 0.260 |
Why?
|
Pregnancy Complications, Infectious | 1 | 2017 | 2026 | 0.260 |
Why?
|
Mortality | 3 | 2021 | 2864 | 0.260 |
Why?
|
Practice Guidelines as Topic | 2 | 2019 | 7279 | 0.260 |
Why?
|
Autoimmune Diseases | 1 | 2017 | 2133 | 0.250 |
Why?
|
Randomized Controlled Trials as Topic | 6 | 2023 | 9959 | 0.250 |
Why?
|
Data Interpretation, Statistical | 3 | 2019 | 2716 | 0.250 |
Why?
|
Alzheimer Disease | 2 | 2022 | 8037 | 0.240 |
Why?
|
Hemorrhage | 4 | 2023 | 3461 | 0.240 |
Why?
|
Young Adult | 21 | 2022 | 56430 | 0.240 |
Why?
|
Multiple Sclerosis | 1 | 2019 | 3079 | 0.240 |
Why?
|
Hypertension | 6 | 2019 | 8480 | 0.240 |
Why?
|
Lupus Erythematosus, Systemic | 1 | 2016 | 2104 | 0.230 |
Why?
|
Adolescent | 17 | 2024 | 85781 | 0.220 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 2 | 2022 | 1518 | 0.220 |
Why?
|
Case-Control Studies | 4 | 2021 | 21746 | 0.220 |
Why?
|
Dose-Response Relationship, Drug | 5 | 2022 | 10943 | 0.220 |
Why?
|
Comorbidity | 5 | 2020 | 10388 | 0.220 |
Why?
|
Cleft Palate | 2 | 2018 | 560 | 0.220 |
Why?
|
Heart Failure, Diastolic | 1 | 2023 | 69 | 0.210 |
Why?
|
Prescription Drugs | 2 | 2021 | 595 | 0.210 |
Why?
|
Kidney | 1 | 2018 | 7186 | 0.210 |
Why?
|
Pyrazoles | 2 | 2023 | 1972 | 0.210 |
Why?
|
Prevalence | 8 | 2021 | 15226 | 0.210 |
Why?
|
Aminosalicylic Acid | 1 | 2021 | 21 | 0.210 |
Why?
|
Angiotensins | 1 | 2022 | 151 | 0.210 |
Why?
|
Smoking | 2 | 2016 | 8987 | 0.200 |
Why?
|
United States Food and Drug Administration | 2 | 2021 | 1584 | 0.200 |
Why?
|
Mycophenolic Acid | 1 | 2024 | 343 | 0.200 |
Why?
|
Anti-Inflammatory Agents | 1 | 2011 | 1790 | 0.200 |
Why?
|
Omeprazole | 1 | 2022 | 112 | 0.200 |
Why?
|
Health Services Accessibility | 1 | 2019 | 5137 | 0.200 |
Why?
|
Cause of Death | 3 | 2021 | 3584 | 0.200 |
Why?
|
Myasthenia Gravis | 1 | 2024 | 199 | 0.200 |
Why?
|
Thioglycolates | 1 | 2021 | 39 | 0.200 |
Why?
|
Herpes Zoster Vaccine | 1 | 2021 | 47 | 0.200 |
Why?
|
Urate Oxidase | 1 | 2021 | 35 | 0.190 |
Why?
|
Acute Chest Syndrome | 1 | 2020 | 31 | 0.190 |
Why?
|
Immunization Schedule | 1 | 2021 | 221 | 0.180 |
Why?
|
Pyridones | 2 | 2023 | 712 | 0.180 |
Why?
|
Medication Therapy Management | 1 | 2021 | 127 | 0.180 |
Why?
|
Retrospective Studies | 17 | 2023 | 77449 | 0.180 |
Why?
|
Prescriptions | 3 | 2021 | 387 | 0.180 |
Why?
|
Infant, Newborn | 13 | 2022 | 25625 | 0.170 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 3 | 2022 | 2282 | 0.170 |
Why?
|
Glucosides | 1 | 2023 | 451 | 0.170 |
Why?
|
Predictive Value of Tests | 4 | 2020 | 15076 | 0.170 |
Why?
|
Causality | 2 | 2024 | 1275 | 0.170 |
Why?
|
Toluidines | 1 | 2019 | 19 | 0.170 |
Why?
|
Crotonates | 1 | 2019 | 19 | 0.170 |
Why?
|
Herpes Zoster | 1 | 2021 | 264 | 0.170 |
Why?
|
Multivariate Analysis | 4 | 2014 | 12245 | 0.170 |
Why?
|
Lawyers | 1 | 2019 | 38 | 0.170 |
Why?
|
Antidepressive Agents | 3 | 2017 | 2838 | 0.170 |
Why?
|
Hydroxybutyrates | 1 | 2019 | 82 | 0.160 |
Why?
|
Time Factors | 11 | 2022 | 40075 | 0.160 |
Why?
|
Spironolactone | 1 | 2022 | 382 | 0.160 |
Why?
|
Sweden | 1 | 2021 | 1345 | 0.160 |
Why?
|
Ondansetron | 1 | 2018 | 90 | 0.160 |
Why?
|
Therapeutic Equivalency | 1 | 2018 | 141 | 0.160 |
Why?
|
Renin-Angiotensin System | 1 | 2022 | 759 | 0.150 |
Why?
|
Sertraline | 1 | 2019 | 206 | 0.150 |
Why?
|
Algorithms | 3 | 2023 | 13881 | 0.150 |
Why?
|
Proton Pump Inhibitors | 1 | 2022 | 526 | 0.150 |
Why?
|
Medical Record Linkage | 1 | 2018 | 284 | 0.150 |
Why?
|
Antiemetics | 1 | 2018 | 177 | 0.150 |
Why?
|
Preoperative Period | 1 | 2019 | 549 | 0.150 |
Why?
|
Benzhydryl Compounds | 1 | 2023 | 845 | 0.150 |
Why?
|
Age Distribution | 2 | 2014 | 2902 | 0.150 |
Why?
|
Postoperative Complications | 1 | 2019 | 15295 | 0.140 |
Why?
|
Geography | 1 | 2019 | 669 | 0.140 |
Why?
|
Carcinoma, Basal Cell | 1 | 2022 | 545 | 0.140 |
Why?
|
Amphetamine | 1 | 2017 | 225 | 0.140 |
Why?
|
Penicillamine | 1 | 2016 | 59 | 0.140 |
Why?
|
Drug Repositioning | 1 | 2018 | 229 | 0.140 |
Why?
|
Quality of Health Care | 1 | 2011 | 4371 | 0.140 |
Why?
|
Citalopram | 1 | 2019 | 403 | 0.140 |
Why?
|
Lung Diseases, Interstitial | 2 | 2021 | 808 | 0.140 |
Why?
|
Opportunistic Infections | 1 | 2019 | 389 | 0.130 |
Why?
|
Nausea | 1 | 2018 | 673 | 0.130 |
Why?
|
Serologic Tests | 1 | 2017 | 374 | 0.130 |
Why?
|
Investments | 1 | 2017 | 143 | 0.130 |
Why?
|
Hyperuricemia | 1 | 2018 | 211 | 0.130 |
Why?
|
Polyethylene Glycols | 1 | 2021 | 1182 | 0.130 |
Why?
|
Triazoles | 1 | 2021 | 911 | 0.130 |
Why?
|
Minocycline | 1 | 2016 | 163 | 0.130 |
Why?
|
Back Pain | 1 | 2019 | 545 | 0.130 |
Why?
|
Pre-Eclampsia | 3 | 2020 | 1200 | 0.130 |
Why?
|
Persistent Fetal Circulation Syndrome | 1 | 2015 | 80 | 0.130 |
Why?
|
Cost-Benefit Analysis | 2 | 2018 | 5391 | 0.130 |
Why?
|
Clinical Coding | 1 | 2016 | 171 | 0.120 |
Why?
|
Postpartum Hemorrhage | 1 | 2018 | 258 | 0.120 |
Why?
|
Bradycardia | 1 | 2016 | 307 | 0.120 |
Why?
|
Sensitivity and Specificity | 3 | 2020 | 14722 | 0.120 |
Why?
|
Codeine | 1 | 2014 | 49 | 0.120 |
Why?
|
Pregnancy Complications, Cardiovascular | 2 | 2016 | 500 | 0.120 |
Why?
|
Hydrocodone | 1 | 2014 | 47 | 0.120 |
Why?
|
Hepatitis B virus | 1 | 2017 | 513 | 0.120 |
Why?
|
Heart Defects, Congenital | 4 | 2018 | 4584 | 0.120 |
Why?
|
Influenza Vaccines | 1 | 2021 | 738 | 0.120 |
Why?
|
Cardiovascular Agents | 1 | 2020 | 850 | 0.120 |
Why?
|
Monte Carlo Method | 1 | 2019 | 1254 | 0.120 |
Why?
|
Infant | 4 | 2020 | 35136 | 0.120 |
Why?
|
Nitriles | 1 | 2019 | 956 | 0.120 |
Why?
|
Cleft Lip | 1 | 2018 | 478 | 0.110 |
Why?
|
Methylphenidate | 1 | 2017 | 473 | 0.110 |
Why?
|
International Classification of Diseases | 1 | 2018 | 867 | 0.110 |
Why?
|
Epidemiology | 1 | 2016 | 287 | 0.110 |
Why?
|
Infusions, Intravenous | 1 | 2018 | 2274 | 0.110 |
Why?
|
Self Report | 2 | 2016 | 3558 | 0.110 |
Why?
|
Meta-Analysis as Topic | 1 | 2018 | 1344 | 0.110 |
Why?
|
Cross-Sectional Studies | 5 | 2021 | 25043 | 0.110 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2017 | 602 | 0.110 |
Why?
|
Longitudinal Studies | 2 | 2019 | 13989 | 0.110 |
Why?
|
Drug Industry | 1 | 2018 | 746 | 0.110 |
Why?
|
Neuralgia | 1 | 2019 | 570 | 0.110 |
Why?
|
Age Factors | 3 | 2020 | 18370 | 0.110 |
Why?
|
Adenosine | 1 | 2017 | 825 | 0.110 |
Why?
|
Physicians, Primary Care | 1 | 2019 | 591 | 0.110 |
Why?
|
Psychotic Disorders | 2 | 2018 | 3046 | 0.110 |
Why?
|
Laxatives | 1 | 2012 | 87 | 0.100 |
Why?
|
Hepatitis B | 1 | 2017 | 695 | 0.100 |
Why?
|
Premature Birth | 3 | 2020 | 1721 | 0.100 |
Why?
|
Calcium Channel Blockers | 1 | 2015 | 690 | 0.100 |
Why?
|
Ticlopidine | 1 | 2017 | 899 | 0.100 |
Why?
|
Ophthalmic Solutions | 1 | 2012 | 317 | 0.100 |
Why?
|
Models, Structural | 1 | 2011 | 361 | 0.100 |
Why?
|
Information Storage and Retrieval | 1 | 2017 | 824 | 0.100 |
Why?
|
Opiate Substitution Treatment | 1 | 2015 | 404 | 0.100 |
Why?
|
Bipolar Disorder | 2 | 2019 | 5027 | 0.100 |
Why?
|
Infant, Newborn, Diseases | 1 | 2016 | 582 | 0.100 |
Why?
|
Myocardial Infarction | 3 | 2022 | 11727 | 0.090 |
Why?
|
Mood Disorders | 1 | 2017 | 1106 | 0.090 |
Why?
|
Adrenergic beta-Antagonists | 1 | 2016 | 1240 | 0.090 |
Why?
|
Bayes Theorem | 1 | 2018 | 2309 | 0.090 |
Why?
|
Influenza, Human | 1 | 2021 | 1479 | 0.090 |
Why?
|
Calcinosis | 1 | 2019 | 1499 | 0.090 |
Why?
|
Enzyme Inhibitors | 1 | 2021 | 3798 | 0.090 |
Why?
|
Cyclophosphamide | 1 | 2016 | 2242 | 0.090 |
Why?
|
Health Services Research | 1 | 2018 | 1836 | 0.090 |
Why?
|
Child | 6 | 2022 | 77709 | 0.090 |
Why?
|
Drug Administration Schedule | 1 | 2018 | 4933 | 0.090 |
Why?
|
Fetal Diseases | 1 | 2015 | 903 | 0.090 |
Why?
|
Diuretics | 1 | 2012 | 592 | 0.090 |
Why?
|
Maternal Exposure | 1 | 2016 | 961 | 0.090 |
Why?
|
Central Nervous System | 1 | 2017 | 1357 | 0.090 |
Why?
|
Hypoglycemia | 1 | 2016 | 861 | 0.080 |
Why?
|
Sex Distribution | 1 | 2014 | 2297 | 0.080 |
Why?
|
Survival Rate | 2 | 2021 | 12788 | 0.080 |
Why?
|
Double-Blind Method | 1 | 2023 | 12026 | 0.080 |
Why?
|
Diabetes, Gestational | 1 | 2018 | 1184 | 0.080 |
Why?
|
Health Expenditures | 1 | 2021 | 2348 | 0.080 |
Why?
|
Arthroplasty, Replacement, Hip | 1 | 2019 | 1462 | 0.080 |
Why?
|
Graft vs Host Disease | 1 | 2020 | 2957 | 0.080 |
Why?
|
Academic Medical Centers | 1 | 2018 | 2759 | 0.080 |
Why?
|
Child, Preschool | 2 | 2020 | 41006 | 0.080 |
Why?
|
Disease Progression | 2 | 2021 | 13284 | 0.070 |
Why?
|
Abruptio Placentae | 2 | 2019 | 118 | 0.070 |
Why?
|
Prognosis | 4 | 2022 | 29063 | 0.070 |
Why?
|
Linear Models | 1 | 2017 | 5952 | 0.070 |
Why?
|
Chi-Square Distribution | 1 | 2013 | 3508 | 0.070 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2022 | 4034 | 0.070 |
Why?
|
Arthritis | 1 | 2011 | 659 | 0.070 |
Why?
|
Prospective Studies | 4 | 2024 | 53288 | 0.070 |
Why?
|
Dermatologic Agents | 2 | 2019 | 278 | 0.060 |
Why?
|
Health Care Surveys | 1 | 2012 | 2453 | 0.060 |
Why?
|
Patient Readmission | 1 | 2019 | 3114 | 0.060 |
Why?
|
Risperidone | 2 | 2018 | 383 | 0.060 |
Why?
|
Residence Characteristics | 1 | 2014 | 2050 | 0.060 |
Why?
|
Hypnotics and Sedatives | 1 | 2012 | 1162 | 0.060 |
Why?
|
Fetal Growth Retardation | 2 | 2019 | 570 | 0.060 |
Why?
|
Bone Density | 1 | 2017 | 3468 | 0.060 |
Why?
|
Antimanic Agents | 2 | 2019 | 522 | 0.060 |
Why?
|
Continuity of Patient Care | 1 | 2011 | 1049 | 0.060 |
Why?
|
Models, Biological | 1 | 2020 | 9583 | 0.060 |
Why?
|
Melanoma | 1 | 2022 | 5510 | 0.060 |
Why?
|
Reproducibility of Results | 2 | 2018 | 19905 | 0.060 |
Why?
|
Pregnancy Trimester, Third | 2 | 2015 | 571 | 0.050 |
Why?
|
Seizures | 1 | 2015 | 2859 | 0.050 |
Why?
|
Skin Neoplasms | 1 | 2022 | 5686 | 0.050 |
Why?
|
Coronary Artery Disease | 2 | 2019 | 6487 | 0.050 |
Why?
|
Attention Deficit Disorder with Hyperactivity | 1 | 2017 | 3658 | 0.050 |
Why?
|
Models, Statistical | 1 | 2017 | 5102 | 0.050 |
Why?
|
Gestational Age | 2 | 2022 | 3493 | 0.050 |
Why?
|
Neoplasms | 2 | 2022 | 21683 | 0.050 |
Why?
|
Health Surveys | 1 | 2011 | 4037 | 0.050 |
Why?
|
Biomedical Research | 1 | 2017 | 3309 | 0.050 |
Why?
|
Primary Health Care | 1 | 2017 | 4558 | 0.050 |
Why?
|
Chronic Disease | 2 | 2017 | 9146 | 0.050 |
Why?
|
Sex Factors | 1 | 2014 | 10397 | 0.050 |
Why?
|
Ambulatory Care | 1 | 2011 | 2708 | 0.050 |
Why?
|
Hypoglycemic Agents | 1 | 2012 | 2872 | 0.050 |
Why?
|
France | 1 | 2021 | 517 | 0.040 |
Why?
|
Pharmacoepidemiology | 1 | 2022 | 323 | 0.040 |
Why?
|
Antibodies, Monoclonal | 1 | 2016 | 9274 | 0.040 |
Why?
|
Deductibles and Coinsurance | 1 | 2021 | 316 | 0.040 |
Why?
|
Uricosuric Agents | 1 | 2018 | 28 | 0.040 |
Why?
|
Hepatitis B Antigens | 1 | 2017 | 40 | 0.040 |
Why?
|
Isotretinoin | 1 | 2019 | 114 | 0.040 |
Why?
|
Pregnancy Outcome | 2 | 2019 | 2795 | 0.040 |
Why?
|
Infant, Small for Gestational Age | 1 | 2020 | 440 | 0.040 |
Why?
|
Carbamazepine | 1 | 2018 | 229 | 0.040 |
Why?
|
Mental Disorders | 1 | 2017 | 6600 | 0.040 |
Why?
|
Hepatitis B Antibodies | 1 | 2017 | 159 | 0.040 |
Why?
|
Amyloid beta-Protein Precursor | 1 | 2022 | 1121 | 0.040 |
Why?
|
Thalidomide | 1 | 2022 | 890 | 0.040 |
Why?
|
Drug and Narcotic Control | 1 | 2018 | 146 | 0.040 |
Why?
|
Labetalol | 1 | 2016 | 30 | 0.040 |
Why?
|
Pregnancy Trimesters | 1 | 2017 | 192 | 0.040 |
Why?
|
Taiwan | 1 | 2017 | 496 | 0.040 |
Why?
|
Adrenergic Uptake Inhibitors | 1 | 2017 | 189 | 0.040 |
Why?
|
Atenolol | 1 | 2016 | 100 | 0.030 |
Why?
|
Metoprolol | 1 | 2016 | 93 | 0.030 |
Why?
|
Pharmaceutical Services | 1 | 2017 | 140 | 0.030 |
Why?
|
Gastrointestinal Hemorrhage | 1 | 2023 | 1130 | 0.030 |
Why?
|
Treatment Failure | 1 | 2022 | 2618 | 0.030 |
Why?
|
Budgets | 1 | 2017 | 229 | 0.030 |
Why?
|
Vomiting | 1 | 2018 | 636 | 0.030 |
Why?
|
Natural Language Processing | 1 | 2023 | 1041 | 0.030 |
Why?
|
Health Services | 1 | 2020 | 758 | 0.030 |
Why?
|
Triazines | 1 | 2017 | 315 | 0.030 |
Why?
|
Patient Simulation | 1 | 2017 | 309 | 0.030 |
Why?
|
Remission Induction | 1 | 2020 | 2386 | 0.030 |
Why?
|
Evidence-Based Practice | 1 | 2018 | 500 | 0.030 |
Why?
|
Myocardial Revascularization | 1 | 2018 | 841 | 0.030 |
Why?
|
Policy | 1 | 2017 | 508 | 0.030 |
Why?
|
Delivery, Obstetric | 1 | 2020 | 906 | 0.030 |
Why?
|
Virus Diseases | 1 | 2019 | 711 | 0.030 |
Why?
|
Pregnant Women | 1 | 2017 | 568 | 0.030 |
Why?
|
Immunocompromised Host | 1 | 2017 | 847 | 0.030 |
Why?
|
Ischemic Attack, Transient | 1 | 2018 | 935 | 0.030 |
Why?
|
Pain, Postoperative | 1 | 2022 | 1643 | 0.030 |
Why?
|
Government Regulation | 1 | 2016 | 522 | 0.020 |
Why?
|
Statistics as Topic | 1 | 2017 | 2373 | 0.020 |
Why?
|
DNA, Viral | 1 | 2017 | 2225 | 0.020 |
Why?
|
Thiazoles | 1 | 2018 | 1483 | 0.020 |
Why?
|
Hypertension, Pregnancy-Induced | 1 | 2016 | 489 | 0.020 |
Why?
|
Bacterial Infections | 1 | 2019 | 1401 | 0.020 |
Why?
|
Patient Protection and Affordable Care Act | 1 | 2020 | 1209 | 0.020 |
Why?
|
Mice, Transgenic | 1 | 2022 | 9734 | 0.020 |
Why?
|
Tobacco Use Disorder | 1 | 2016 | 688 | 0.020 |
Why?
|
Amyloid beta-Peptides | 1 | 2022 | 3587 | 0.020 |
Why?
|
Central Nervous System Stimulants | 1 | 2017 | 1148 | 0.020 |
Why?
|
Poverty | 1 | 2020 | 2660 | 0.020 |
Why?
|
Odds Ratio | 1 | 2021 | 9849 | 0.020 |
Why?
|
Outpatients | 1 | 2016 | 1486 | 0.020 |
Why?
|
Income | 1 | 2017 | 1913 | 0.020 |
Why?
|
Evidence-Based Medicine | 1 | 2020 | 3610 | 0.020 |
Why?
|
Piperazines | 1 | 2018 | 2488 | 0.020 |
Why?
|
Patient Selection | 1 | 2018 | 4215 | 0.020 |
Why?
|
Liver Cirrhosis | 1 | 2016 | 1863 | 0.020 |
Why?
|
Antihypertensive Agents | 1 | 2015 | 2046 | 0.020 |
Why?
|
Hepatitis C | 1 | 2016 | 1591 | 0.020 |
Why?
|
Phenotype | 1 | 2022 | 16365 | 0.020 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 1 | 2019 | 3047 | 0.020 |
Why?
|
Kidney Diseases | 1 | 2016 | 2149 | 0.020 |
Why?
|
Inpatients | 1 | 2016 | 2518 | 0.020 |
Why?
|
Disease Models, Animal | 1 | 2022 | 18029 | 0.010 |
Why?
|
Quality of Life | 1 | 2024 | 12804 | 0.010 |
Why?
|
Healthcare Disparities | 1 | 2017 | 3158 | 0.010 |
Why?
|
Epilepsy | 1 | 2017 | 3310 | 0.010 |
Why?
|
Anxiety | 1 | 2016 | 4297 | 0.010 |
Why?
|
Asthma | 1 | 2019 | 6011 | 0.010 |
Why?
|
Substance-Related Disorders | 1 | 2016 | 4258 | 0.010 |
Why?
|
Depression | 1 | 2016 | 7766 | 0.010 |
Why?
|
Mice | 1 | 2022 | 81183 | 0.010 |
Why?
|
Animals | 1 | 2022 | 168757 | 0.010 |
Why?
|
HIV Infections | 1 | 2016 | 16718 | 0.010 |
Why?
|